LAS190792

also known as Azd 8999

Small molecule targets ADRB2, CHRM3 via activation / inhibition

today NCT02059434 · Ph 1

20142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT02059434	Sep 2013 → Oct 2014	asthma, chronic obstructive pulmonary disease	AstraZeneca	Completed	Met primary

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	LAS190792	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02059434 ↗
Known as	Azd 8999	ChEMBL registry synonym — accepted as the source's own label CHEMBL3916700 ↗
Action	Activate	“Beta-2 adrenergic receptor agonist” CHEMBL3916700 ↗
Action	Inhibit	“Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3916700 ↗
Modality	Small molecule	— CHEMBL3916700 ↗
Route	Inhaled	“administered by inhalation” NCT02059434 ↗
Target	ADRB2	“Beta-2 adrenergic receptor agonist” CHEMBL3916700 ↗
Target	CHRM3	“Muscarinic acetylcholine receptor M3 antagonist” CHEMBL3916700 ↗